Literature DB >> 2994068

The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.

D R Illingworth, D Corbin.   

Abstract

The biosynthesis of adrenal corticosteroids in humans depends on a continuous supply of cholesterol, which can be derived from both local synthesis and receptor-mediated uptake of low density lipoproteins (LDL) from plasma. Mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase [mevalonate:NAD+ oxidoreductase (CoA-acylating), EC 1.1.1.88] is an effective hypolipidemic agent in patients with heterozygous familial hypercholesterolemia. To determine whether mevinolin influences the adrenal production of corticosteroids, the adrenocortical response to a continuous 36-hr infusion of corticotropin (ACTH) was examined in eight patients with heterozygous familial hypercholesterolemia before, and again during, treatment with mevinolin (40-80 mg/day). The drug produced an average decrease of 28% and 34% in the plasma concentrations of total and LDL cholesterol. Serum cortisol levels showed similar increases in response to ACTH stimulation before and during mevinolin treatment, and the rates of excretion of urine-free cortisol were also similar. We conclude that clinically effective doses of mevinolin do not affect corticosteroid production by the adrenal cortex during prolonged ACTH stimulation in patients with heterozygous familial hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994068      PMCID: PMC391039          DOI: 10.1073/pnas.82.18.6291

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Receptor-mediated uptake of lipoprotein-cholesterol and its utilization for steroid synthesis in the adrenal cortex.

Authors:  M S Brown; P T Kovanen; J L Goldstein
Journal:  Recent Prog Horm Res       Date:  1979

2.  The use of intravenous ACTH: a study in quantitative adrenocortical stimulation.

Authors:  A E RENOLD; D JENKINS; P H FORSHAM; G W THORN
Journal:  J Clin Endocrinol Metab       Date:  1952-07       Impact factor: 5.958

3.  The 48-hour adrenocorticotrophin infusion test for adrenocortical insufficiency.

Authors:  L I Rose; G H Williams; P I Jagger; D P Lauler
Journal:  Ann Intern Med       Date:  1970-07       Impact factor: 25.391

Review 4.  The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands.

Authors:  J T Gwynne; J F Strauss
Journal:  Endocr Rev       Date:  1982       Impact factor: 19.871

5.  Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.

Authors:  S M Grundy; D W Bilheimer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Effects of adrenocorticotropic hormone on low density lipoprotein receptors of human fetal adrenal tissue.

Authors:  M Ohashi; B R Carr; E R Simpson
Journal:  Endocrinology       Date:  1981-04       Impact factor: 4.736

7.  Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

Authors:  J A Tobert; G D Bell; J Birtwell; I James; W R Kukovetz; J S Pryor; A Buntinx; I B Holmes; Y S Chao; J A Bolognese
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

8.  Adrenal function in heterozygous and homozygous hypobetalipoproteinemia.

Authors:  D R Illingworth; T A Kenny; E S Orwoll
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

9.  Therapeutic effects of ML-236B in primary hypercholesterolemia.

Authors:  A Yamamoto; H Sudo; A Endo
Journal:  Atherosclerosis       Date:  1980-03       Impact factor: 5.162

10.  Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.

Authors:  D R Illingworth
Journal:  Ann Intern Med       Date:  1984-11       Impact factor: 25.391

View more
  10 in total

Review 1.  Clinical implications of new drugs for lowering plasma cholesterol concentrations.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

2.  [Lipid status and basal steroid hormone level following 16 weeks of lovastatin therapy in primary hypercholesterolemia].

Authors:  W Stürmer; E P Kromer; A J Riegger; K Kochsiek
Journal:  Klin Wochenschr       Date:  1991-05-03

Review 3.  Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.

Authors:  J M Henwood; R C Heel
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

4.  Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia.

Authors:  J Thiery; A K Walli; G Janning; D Seidel
Journal:  Eur J Pediatr       Date:  1990-07       Impact factor: 3.183

5.  Effects of mevinolin, an inhibitor of cholesterol synthesis, on the morphology and function of differentiating and differentiated rat adrenocortical cells in primary culture.

Authors:  P Heikkilä; A I Kahri; P T Kovanen; C Ehnholm
Journal:  Cell Tissue Res       Date:  1990-07       Impact factor: 5.249

Review 6.  Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

7.  Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.

Authors:  R H Jay; R H Sturley; C Stirling; H H McGarrigle; M Katz; J P Reckless; D J Betteridge
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

8.  Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients.

Authors:  G P Bernini; G F Argenio; M Gasperi; M S Vivaldi; F Franchi; A Salvetti
Journal:  J Endocrinol Invest       Date:  1994-04       Impact factor: 4.256

9.  Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients.

Authors:  G P Bernini; G Brogi; G F Argenio; A Moretti; A Salvetti
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

10.  Effects of evolocumab therapy and low LDL-C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes.

Authors:  Dirk J Blom; Jiyan Chen; Zuyi Yuan; Joao L C Borges; Maria L Monsalvo; Nan Wang; Andrew W Hamer; Junbo Ge
Journal:  Endocrinol Diabetes Metab       Date:  2020-03-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.